INM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
INM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Days Inventory is also known as Days Sales of Inventory (DSI). InMed Pharmaceuticals's Average Total Inventories for the three months ended in Dec. 2024 was $1.16 Mil. InMed Pharmaceuticals's Cost of Goods Sold for the three months ended in Dec. 2024 was $0.65 Mil. Hence, InMed Pharmaceuticals's Days Inventory for the three months ended in Dec. 2024 was 162.81.
The historical rank and industry rank for InMed Pharmaceuticals's Days Inventory or its related term are showing as below:
During the past 13 years, InMed Pharmaceuticals's highest Days Inventory was 1668.28. The lowest was 128.66. And the median was 274.25.
InMed Pharmaceuticals's Days Inventory increased from Dec. 2023 (93.54) to Dec. 2024 (162.81). It might indicate that InMed Pharmaceuticals's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year. InMed Pharmaceuticals's Inventory Turnover for the three months ended in Dec. 2024 was 0.56.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. InMed Pharmaceuticals's Inventory-to-Revenue for the three months ended in Dec. 2024 was 1.04.
The historical data trend for InMed Pharmaceuticals's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InMed Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Jun20 | Jun21 | Jun22 | Jun23 | Jun24 | |||||||||||
Days Inventory | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | 1,668.28 | 274.25 | 149.26 |
InMed Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Days Inventory | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
93.54 | 100.08 | 136.15 | 145.62 | 162.81 |
For the Drug Manufacturers - Specialty & Generic subindustry, InMed Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, InMed Pharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where InMed Pharmaceuticals's Days Inventory falls into.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
InMed Pharmaceuticals's Days Inventory for the fiscal year that ended in Jun. 2024 is calculated as
Days Inventory (A: Jun. 2024 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (A: Jun. 2023 ) | + | Total Inventories (A: Jun. 2024 )) | / | count ) | / | Cost of Goods Sold (A: Jun. 2024 ) | * | Days in Period |
= | ( (1.616 | + | 1.244) | / | 2 ) | / | 3.497 | * | 365 |
= | 1.43 | / | 3.497 | * | 365 | ||||
= | 149.26 |
InMed Pharmaceuticals's Days Inventory for the quarter that ended in Dec. 2024 is calculated as:
Days Inventory (Q: Dec. 2024 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (Q: Sep. 2024 ) | + | Total Inventories (Q: Dec. 2024 )) | / | count ) | / | Cost of Goods Sold (Q: Dec. 2024 ) | * | Days in Period |
= | ( (1.22 | + | 1.103) | / | 2 ) | / | 0.651 | * | 365 / 4 |
= | 1.1615 | / | 0.651 | * | 365 / 4 | ||||
= | 162.81 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InMed Pharmaceuticals (NAS:INM) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
InMed Pharmaceuticals's Inventory Turnover for the three months ended in Dec. 2024 is calculated as
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 0.651 | / | 1.1615 | |
= | 0.56 |
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
InMed Pharmaceuticals's Inventory to Revenue for the three months ended in Dec. 2024 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 1.1615 | / | 1.112 | |
= | 1.04 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Thank you for viewing the detailed overview of InMed Pharmaceuticals's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Mancini Alexandra Diane Janet | officer: Sr VP, Clinical Reg Affairs | C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4 |
Andrew Hull | director | C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4 |
Eric A Adams | director, officer: President & CEO | C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4 |
Jonathan Tegge | officer: Interim CFO | 217 W. MAIN STREET, SOMERVILLE NJ 08876 |
Sarah Li | officer: VP, Accounting and Controller | 310-815 WEST HASTINGS ST., VANCOUVER Z4 V6C1B4 |
Nicole Lemerond | director | 3 MURRAY HILL ROAD, SCARSDALE NY 10583 |
Bryan T Baldasare | director | 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244 |
Brenda Edwards | officer: Interim CFO | 111-1232 JOHNSON ST., COQUITLAM A1 V3B 4T2 |
Janet P Grove | director | 510 WEST GEORGIA STREET, SUITE 1800, VANCOUVER A1 V5T 4T5 |
Bruce Colwill | officer: CFO | C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4 |
Shane Aaron Johnson | officer: SVP & GM of BayMedica LLC | 930 TAHOE BLVD., SUITE 802-433, INCLINE VILLAGE NV 89451 |
Adam D. Cutler | director | 9301 AMBERGLEN BOULEVARD, SUITE 100, C/O MOLECULAR TEMPLATES, INC., AUSTIN TX 78729 |
William J Garner | director | 875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010 |
Catherine Sazdanoff | director | 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244 |
Eric C Hsu | officer: Sr. VP, Pre-Clinical Res/Dev | C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4 |
From GuruFocus
By GlobeNewswire GlobeNewswire • 08-23-2022
By Value_Insider Value_Insider • 11-10-2022
By Value_Insider Value_Insider • 10-26-2022
By GuruFocus Research • 03-06-2024
By Stock market mentor Stock market mentor • 01-10-2023
By GuruFocus News • 01-04-2025
By GlobeNewswire GlobeNewswire • 07-13-2022
By Value_Insider Value_Insider • 11-16-2022
By GuruFocus Research • 03-06-2024
By Value_Insider Value_Insider • 12-16-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.